相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)-The short-term results of cohort A and B.
Shun Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Weilei Hu et al.
ISCIENCE (2020)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PD-1 Inhibitors in the Advanced Esophageal Cancer
Ye Hong et al.
FRONTIERS IN PHARMACOLOGY (2019)
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer
Toshifumi Yamaguchi et al.
GASTRIC CANCER (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Immune checkpoint inhibitors in malignancy
Luke Ardolino et al.
AUSTRALIAN PRESCRIBER (2019)
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Jing Huang et al.
CLINICAL CANCER RESEARCH (2018)
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
Hideaki Bando et al.
EUROPEAN JOURNAL OF CANCER (2018)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Lordick et al.
ANNALS OF ONCOLOGY (2016)
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
Tobias Janowitz et al.
BRITISH JOURNAL OF CANCER (2016)
Esophageal Carcinoma
Anil K. Rustgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy
Ken Kato et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
Taroh Satoh et al.
CANCER SCIENCE (2011)
A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy
Ayako Mizota et al.
ONCOLOGY (2011)
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
E Marcuello et al.
BRITISH JOURNAL OF CANCER (2004)
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
K Muro et al.
ANNALS OF ONCOLOGY (2004)
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma
F Mühr-Wilkenshoff et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2003)
Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407)
K Hayashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
